To include your compound in the COVID-19 Resource Center, submit it here.

Angiomax bivalirudin: Marketed to treat unstable angina in patients undergoing angioplasty

In the post-marketing Phase IIIb/IV REPLACE-2 trial in 6,002 patients with unstable angina undergoing percutaneous translumenal coronary angioplasty (PTCA),

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE